A skin health specialist, which raised £4.5m when it listed on the London stock market last week, will use the funds to drive forward its probiotic technology for skin health applications.
SkinBioTherapeutics, a University of Manchester spin-out, will focus on developing and commercialising its SkinBiotix technology platform.
The funds raised will enable it to focus on its development portfolio of three programmes – in skin care (sensitive skin), anti-infection and eczema.
Disclaimer: The opinions expressed by our writers are their own and do not represent the views of Precise Investors. The information provided on Precise Investors is intended for informational purposes only. Precise Investors is not liable for any financial losses incurred. Conduct your own research by contacting financial experts before making any investment decisions.
